RxDoctor Payments DataLook up a doctor →

Benjamin Close, MD

Pediatric Allergy/Immunology · Alexandria, LANPI 1730185802

Payments from drug & device makers

$420,615in general payments, 2019–2025

Across 1,468 payments — averaging $286.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$207K
  • Sanofi$63K
  • Regeneron Healthcare Solutions, Inc.$57K
  • GSK$42K
  • Amgen$17K
  • Genentech USA, Inc.$14K
  • plus $21K from 36 others

What the payments were for

  • Consulting fees$42,26410%
  • Speaking & faculty fees$321,00776%
  • Travel & lodging$26,1336%
  • Food & beverage$30,8877%
  • Education$3240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric allergy/immunology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,106,634
Medicare patients
517
Services billed
36,786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter478$350,333
Dupixent SyringeDupilumab79$343,786
Dupixent PenDupilumab84$334,189
NucalaMepolizumab42$148,929
HizentraImmun Glob G(Igg)/Pro/Iga 0-5022$144,360
Fasenra PenBenralizumab26$142,862
TezspireTezepelumab-Ekko33$134,928
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5026$125,644
FasenraBenralizumab14$86,661
Breo ElliptaFluticasone/Vilanterol122$57,483
XolairOmalizumab19$43,173
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$31,168
SymbicortBudesonide/Formoterol Fumarate71$21,141
Fluticasone-SalmeterolFluticasone Propion/Salmeterol119$15,883
Spiriva RespimatTiotropium Bromide23$11,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta$41,510$563,286675 claims
AstraZenecaTezspire, Fasenra, Breztri Aerosphere, Symbicort$206,623$273,898162 claims
CSL BehringHizentra, Privigen$12,729$270,00448 claims
Boehringer IngelheimSpiriva Respimat$118$11,54623 claims
Hikma Pharmaceuticals USAEpinephrine$265$7,75331 claims
MerckDulera$30$3,38111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric allergy/immunology providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other pediatric allergy/immunology in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →